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Abstract
Background: People with multiple sclerosis (MS) are at high risk of depression. We undertook a pilot trial of
computerised cognitive behavioural therapy (CCBT) for the treatment of depression in people with MS to test the
feasibility of undertaking a full trial.
Methods: Participants with a diagnosis of MS and clinical levels of depression were recruited through out-patient clinics
and postal screening questionnaires at two UK centres and randomised to CCBT or usual care. Clinical outcomes
included the Beck Depression Inventory (BDI-II) and Multiple Sclerosis Impact Scale (MSIS-29) at baseline, 8 and 21 weeks.
Feasibility outcomes included: recruitment rate; reasons for refusal, withdrawal and dropout; feasibility and acceptability
of the proposed outcome measures; sample size estimation and variation in and preferences for service delivery.
Results: Twenty-four participants were recruited. The recruitment rate, calculated as the proportion of those invited
to fill in a screening questionnaire who were consented into the trial, was 4.1%. Recruitment through out-patient
clinics was somewhat slower than through screening questionnaire mail-out but the overall recruitment yield was
similar. Of the 12 patients in the CCBT arm, 9 (75%) completed at least four, and 6 completed all 8 CCBT sessions.
For completers, the median time (IQR) to complete all eight CCBT sessions was 15 (13 to 20) weeks. Participants
expressed concern about the face validity of the Beck Depression Inventory II for the measurement of self-reported
depression in people with MS. The MSIS-29 was the patient-reported outcome measure which participants felt best
reflected their concerns. The estimated sample size for a full trial is between 180 and 390 participants. NHS
partners were not delivering CCBT in community facilities and participants preferred to access CCBT at home, with
no one expressing a preference for use of CCBT in an alternative location.
Conclusions: A definitive trial, with a recruitment window of one year, would require the participation of around
13 MS centres. This number of centres could be reduced by expanding the eligibility criteria to include either other
neurological conditions or people with more severe depression. The MSIS-29 should be used as a patient-
important outcome measurement.
Trial registration: ISRCTN: ISRCTN81846800
Background
Multiple Sclerosis (MS) is a chronic immune mediated
disease of the central nervous system which affects
around 0.1% of Caucasians of north and central Eur-
opean ancestry [1]. MS is characterized by a variety of
symptoms including visual impairment, limb weakness,
sensory disturbance, balance and postural problems,
sphincter dysfunction, cognitive impairments, pain and
fatigue [2]. In the majority of patients, the illness runs
an initial relapsing remitting (RRMS) course character-
ized by episodes of acute neurological dysfunction fol-
lowed by full or partial recovery, usually culminating in
a secondary progressive (SPMS) course during which
disability progresses gradually with or without
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occasional relapses, minor remissions and plateaus [3].
Reports suggest that 50% of patients with MS experience
major depression during their lifetime and up to 40%
may have depression at any one time [4,5]. A Cochrane
review, last updated in mid-2005, suggested there was
some evidence that cognitive behavioural therapy (CBT)
could be effective for the treatment of depression in
people with MS [6].
The UK National Institute for Health and Clinical
Excellence (NICE) recommends Cognitive Behavioural
Therapy (CBT) as a treatment for mild to moderate
depression, and there has been an increasing interest in
its use to help people to remain in the workplace [7-9].
As therapist-led CBT is often inaccessible or prohibi-
tively expensive, computerised CBT (CCBT) is recom-
mended by NICE as part of a stepped-care model for
the management of mild or moderate depression, typi-
cally delivered in a primary care setting [10,11]. NICE
recommended one package in particular, Beating the
Blues, for treatment of mild to moderate depression
[10]. However, the management of mental health pro-
blems is often complicated by the co-presence of
chronic physical illness, and treatments which have been
validated in populations without chronic physical illness
may not be appropriate or effective in such circum-
stances [12]. More recent NICE guidance recommends
CCBT for the treatment of depression in people with
chronic physical conditions whilst recommending that
further randomised controlled trials of psychological
interventions are undertaken for this population [13].
Because of the challenges inherent in evaluating com-
plex interventions such as CCBT, the Medical Research
Council’s Complex Intervention Framework recom-
mends a stepwise approach to evaluation, with pilot
work preceding a full randomised controlled trial (RCT)
[14]. The full study would be an RCT with economic
evaluation alongside the trial to test the hypothesis that
CCBT is clinically and cost-effective, compared to usual
treatment, for the treatment of depression in people
with MS. In a previous paper we reported qualitative
research assessing the target group’s views on the
acceptability and appropriateness of CCBT [15]. In this
paper we report the results of a pilot trial, designed to
assess the feasibility of a research protocol for a multi-
centre trial and to estimate the variance of the treat-
ment effect. The pilot trial did not attempt to provide
evidence for the clinical effectiveness of CCBT for the
treatment of depression in people with MS. Therefore,
we have written up our findings in accordance with
recommendations for CONSORT-modifications for
reporting the results of pilot studies and pragmatic trials
[16,17].
The objectives of this pilot trial were to:
• identify recruitment rates and test practicalities of
recruitment;
• identify withdrawal and dropout rates during treat-
ment phase and three month follow up phase to
estimate dropout over longer term;
• identify reasons for refusal, withdrawal and
dropout;
• test feasibility and acceptability of the proposed
outcome measures, including the client service
receipt inventory (a questionnaire developed for the
collection of information on costs, service utilisation
and related matters) required for a full economic
evaluation;
• identify effect size and its associated variability at
end of treatment in order to calculate an appropriate
sample size for the full trial;
• identify variation in use or delivery of the interven-
tion both at home and in an external setting;
• identify rate of preference for use of intervention at
home or elsewhere
Methods
Participants and setting
We invited 582 people diagnosed with MS to screen for
a study evaluating an intervention for low mood by
completing a screening questionnaire including prognos-
tic and eligibility criteria and a copy of the Beck Depres-
sion Inventory II-21 Item (BDI) [18]. All invitees had
relapsing remitting or secondary progressive MS,
according to the modified McDonald criteria [19]. Invi-
tations were made between October 2008 and July 2009:
face-to-face by consultants in the Sheffield Teaching
Hospitals NHS Foundation Trust MS clinic (n = 288);
by the Sheffield MS nurses visiting patients (n = 4); and,
using ink-signed personalised letters mailed out from a
neuropsychologist at Sheffield (n = 40) as well as from
consultant neurologists at the Walton Centre for Neu-
rology and Neurosurgery NHS Trust, Liverpool (n =
250). At Sheffield potential participants were identified
from clinic attenders, MS nurse patient visits and from
patients with MS from the caseload of the neuropsy-
chologist. At the Walton Centre potential participants
were identified solely from the MS register. The MS ser-
vices in both sites are specific entities and not general
neurology clinics.
Respondents completed a second BDI before a screen-
ing interview at which they were screened for eligibility
by a clinical psychologist. Inclusion criteria were: age of
18 years or above; BDI score of at least 14 on two con-
secutive occasions and no treatment from psychologist,
psychotherapist or psychiatrist within the last three
months. That is, the sample was rated as depressed,
using the BDI, but was not necessarily self-identifying
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and treatment-seeking. Exclusion criteria were: poor
English language skills or cognitive function (score of
less than 24 on Mini Mental State Examination [20]);
BDI score of at least 29 on two consecutive occasions;
active suicidal ideas; current or life-time diagnosis of
psychosis, organic mental disorder or substance depen-
dency; Kurtzke Expanded Disability Status Scale (EDSS)
score of 8.5 or above [21]). The EDSS is a tool for quan-
tifying MS-related disability. Our threshold for ineligibil-
ity was intended to exclude those who were restricted to
bed for much of the day and had only limited use of
their arms, thus effectively precluding use of a computer
mouse and keyboard. The clinical psychologist assessed
participants for major depressive disorder using the
Mini-International Neuropsychiatric Interview (MINI)
[22], but this was not an eligibility criterion.
Potential participants who were identified as having
severe depression (BDI score of at least 29) or active
suicidal ideas during the screening process were con-
tacted by the study clinical psychologists and briefly
assessed to understand whether the reported symptoms
were typical and advised to contact their GP if deemed
necessary. Once recruited to the study, active monitor-
ing of Beck Depression Inventory responses was the
responsibility of the study manager who contacted the
PCT mental health lead on identifying responses indi-
cating active suicidal ideation. Responses were dealt
with according to the primary care trust’s individual
protocols for handling suicidal ideation.
Interventions
After consent, we randomised participants either to
CCBT using ‘Beating the Blues’® (Ultrasis Ltd) or to
usual care (Treatment as Usual - TAU). A central web-
based randomisation service delivered by the Sheffield
Clinical Trials Research Unit was used after patient elig-
ibility had been confirmed. All TAU arm participants
were offered the opportunity of accessing the interven-
tion at the end of the trial. The study statisticians and
principal investigator remained blinded to the treatment
allocation codes until after the final analysis. Beating the
Blues® consists of eight computer-interactive sessions,
of approximately 50 minutes each in duration, designed
to be taken weekly. Each session consists of a mix of
cognitive and behavioural strategies, which the user cus-
tomises to their individual problems. A client service
receipt inventory was used at baseline, 8 weeks and 21
weeks to identify concomitant medication and service
use in both arms: the research protocol did not manua-
lise or restrict treatment as usual.
Clinical outcomes
The primary clinical endpoint was the mean change in
self-reported symptoms of depression as measured on
the BDI. Specifically, we measured the mean change in
scores between the two arms as measured at baseline,
8 and 21 weeks (13 weeks post intervention). Second-
ary clinical endpoints, measured at the same time
points, were: (1) MS specific Quality of Life (QoL),
measured by the Multiple Sclerosis Impact Scale 29-
item (MSIS-29 [23]) questionnaire (physical and psy-
chological components); general health related QoL,
measured by the summary score for the Short Form-36
items (SF-36 [24]); overall improvement of depression
severity and anxiety, measured by Patient Health Ques-
tionnaire-9 item (PHQ-9 [25]) and Generalised Anxiety
Disorder 7-item (GAD-7 [26]) questionnaires respec-
tively. A client service receipt inventory was used to
capture concomitant use of health services and medi-
cation between follow-ups, to test collection of cost
and activity data.
Feasibility outcomes
The pre-specified primary outcome was the recruitment
rate, calculated as the proportion of those invited to fill
in a screening questionnaire who were consented into
the trial. The practicalities of recruitment were assessed
descriptively (see next paragraph). Refusal, withdrawal
and dropout from the study protocol were recorded.
The feasibility, acceptability and appropriateness of data
collection strategies were assessed descriptively and
through item response rates. Variation in the delivery of
CCBT by Primary Care Trusts (PCTs) was documented,
in terms of whether they made provision for use at
home and the level of support. Rates of preference for
use of the intervention at home and withdrawal from
treatment were calculated as a percentage of those
randomised.
A short semi-structured telephone interview was con-
ducted with all study participants on completion of
CCBT during which they were asked how they felt
about the processes of recruitment and randomisation,
the location of CCBT, their reasons for dropping out or
not completing (where appropriate) and the appropriate-
ness of the quantitative outcome measures used in the
study. The methods for data collection and analysis of
this qualitative component have been reported pre-
viously [15].
Feasibility criteria
No criteria for evaluating the feasibility (in the sense of
formal ‘stop/go’ criteria) of a definitive study were iden-
tified prospectively (see discussion).
Sample size
We used a sample size of 12 per group (n = 24), on the
basis of feasibility and precision of estimates to be used
to design the main study [27].
Cooper et al. Trials 2011, 12:259
http://www.trialsjournal.com/content/12/1/259
Page 3 of 14
Statistical methods
Primary analysis was an Intention To Treat (ITT) analy-
sis which analysed all 24 participants according to their
randomised treatment assignment ignoring non compli-
ance, protocol deviations and withdrawal. Statistical ana-
lysis was mainly descriptive [16] with outcome
variability and patient response profiles analysed using
summary measures at different time points. For this
study, and in planning future studies it is most useful to
present the absolute final values for individuals, rather
than by how much individuals change from their initial
baseline values as this allows comparison with popula-
tion norms and other population groups. For these rea-
sons we have presented the former rather than the latter
as it provides the necessary information about both
change and absolute values. Response rates on question-
naire items were high and last observation carried for-
ward was used to impute the few missing items.
Questionnaire response rates are given as a fraction of
the total number of questions answered in a question-
naire among patients followed up on a specific visit rela-
tive to the total items. For example, the denominators
for BDI and MSIS-29 are 21 and 29 questions respec-
tively. Sample size calculation for a definitive trial was
performed using an ANCOVA model, approximated
standardised effect sizes corresponding to small, med-
ium and large effect sizes, expected drop out rate, out-
come variability and conservative correlation structure
from this pilot study. All analysis was performed in
Stata version 11.1.
Ethical approval
This study received ethics approval from Northern and
Yorkshire Research Ethics Committee.
Results
Recruitment rates and practicalities of recruitment
Our initial aim was to recruit 24 participants between
22 October 2008 and 31 January 2009 (101 days; 7.1
participants/month) with candidates identified by three
neurologists working in a single weekly specialist MS
clinic (Sheffield Teaching Hospitals NHS Trust). We
reached our recruitment target on 30 July 2009 (in 281
days; 2.6 participants/month) after adding a second cen-
tre (The Walton Centre NHS Foundation Trust, Liver-
pool). From the 288 invitation packs given out by
Sheffield neurologists in the MS clinic, forms were com-
pleted and returned by 63 (21.8%) candidates from
which we randomised 13 in 281 days (4.5% recruitment
yield), or 1.4 participants per month. From the 250
recruitment packs sent out by post from The Walton
Centre, forms were completed and returned by 64
(25.6%) of recipients, from which 10 participants were
randomised in 149 days (4.0% recruitment yield), or two
participants per month. Sheffield MS Nurses approached
four patients and a further participant was identified and
recruited in this way. A neuropsychologist, based in
Sheffield also wrote to 40 patients, but none of the
respondents were recruited. In the telephone interviews,
no participants expressed any concern about the pro-
cesses of recruitment and randomisation.
Participant characteristics
As this was a pilot study the sample size was small and
by chance the random allocation of participants to the
intervention and control groups resulted in imbalances
between the groups at baseline with respect to gender,
MS type and depression severity (Table 1).
Refusal, withdrawal and dropout
Of 582 patients invited to take part, 140 responded of
whom 48 were not interested in participating, 68 were
ineligible and 24 were randomised (Figure 1). Therefore
the primary outcome, the recruitment rate, calculated as
the proportion of those invited to fill in a screening
questionnaire consented into the trial, was 4.1%. Of
those who responded but were ineligible: 41 suffered
from minimal depression (BDI of 13 or less); 20 were
suffering from severe depression (BDI of 29 of more on
two separate occasions); five were already seeing a psy-
chiatrist or similar; and two were living in non-partici-
pating PCTs. Two participants in each arm were lost to
follow-up at 21 weeks post-randomisation. No patients
were formally withdrawn from the study.
Feasibility, acceptability, appropriateness of data
collection strategies
The collection of outcome data by postal questionnaire
proved to be challenging, with multiple attempts to
obtain data from many participants, particularly at
later outcome assessment points. Nevertheless, primary
outcome assessments were available for 21 (88%) parti-
cipants at 8 weeks from randomisation (or end of
treatment if later) and 18 (75%) participants at a
further three months ’ follow-up. Furthermore, the
completion rate for those questionnaires returned was
high (Table 2).
The patient reported outcome measure which the par-
ticipants felt best reflected their concerns was the MSIS-
29. During the telephone interviews, participants
expressed concern about the face validity, for people
with MS, of the questionnaires used for the measure-
ment of self-reported depression, including the Beck
Depression Inventory II. In particular they were con-
cerned about the three symptoms, fatigue, sleep and
concentration, which are also somatic symptoms of MS.
“[The questions are] not really appropriate for people
with MS because they are things that you would have
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anyway. They’re not actually concerned with depression
like not having good sleep. I mean, that’s a very com-
mon problem with MS is you don’t have refreshing
sleep.” (ID 271)
No issues were identified with the client service
receipt inventory designed for the collection of cost and
activity data. Identification of prognostic variables, parti-
cularly the EDSS and MS Type, from patient records
was not always possible and had to be obtained directly
from participants’ neurologists for the purposes of the
study in some cases.
Variability of outcome measures and sample size
estimation
Patient profiles with respect to clinical outcomes are
reported in Table 3 and Figures 2, 3, 4 and 5. The usual
approach to estimating sample size is to base it on an
important clinically significant change. However, the dif-
ficulties of assessing a clinically significant change in
BDI in the MS population have been reported previously
with no available guideline [28]. An alternative approach
is to base the effect size on the estimated mean change
in BDI between the two groups. We decided against
doing this as baseline imbalances with respect to gender
and MS-type (Table 1) would produce bias in the esti-
mated intervention effect.
Instead we used approximate effect sizes expressed as a
fraction of the pooled standard deviation of outcomes
from this pilot which correspond to small, moderate and
large standardised effect sizes. The standard deviations of
the BDI, MSIS-29 psychological and physical domains
were 8.3, 8.2 and 18.2 respectively, and variability of
these outcome measures stratified by intervention group
are shown in Table 4. Data at all time-points were
included in these calculations and as such provide con-
servative estimates of the true standard deviation for
these measures. The results related to the change in BDI
and MSIS among complete cases are given in Table 5.
A mean difference of change in 5 points on the BDI
corresponds to a moderate standardised effect size and
equates to the upper estimate of the likely effect size
[29]. To have 90% power to detect this effect size
(assuming correlation between follow-up measurements
of 0.75, an attrition rate of 25% and a fixed type 1 error
rate of 5%) a total of 70 participants would be required.
A difference between groups of 3 or 2 points would cor-
respond to the lower estimates of the likely effect size
and this would require a total sample size of 180 and
390 respectively at 90% power. The summary of sample
size estimates at varying levels of power and effect size
(expressed as an absolute value and as equivalent stan-
dardised effect size) are given in Table 6.
Table 1 Participant baseline characteristics
Characteristic Scoring TAU3 CCBT4 Total
(n = 12) (n = 12) (N = 24)
n (%) n (%) n (%)
Gender Male 5 (42%) 1 (8%) 6 (25%)
Female 7 (58%) 11 (92%) 18 (75%)
Age (years)
Min to max 31 to 54 33 to 57 31 to 57
Mean (SD)1 42 (7.0) 48 (7.7) 45 (7.9)
Median (IQR)2 42 (37 to 47) 49.8 (42 to 55) 45 (39 to 51)
EDSS score
Min to max 0.0 to 6.0 2.0 to 6.5 0.0 to 6.5
Mean (SD) 3.6 (1.8) 4.8 (1.7) 4.2 (1.8)
Median (IQR) 3.5 (2.8 to 5.0) 5.5 (3.5 to 6.3) 4.0 (3.0 to 6.0)
Centre
Liverpool 5 (42%) 5 (42%) 10 (42%)
Yorkshire 7 (58%) 7 (58%) 14 (58%)
MS type
Relapsing-remitting 12 (100%) 7 (58%) 19 (79%)
Primary progressive 0 (0%) 5 (42%) 5 (21%)
BDI total score (0 weeks)
Min to max 15 to 29 16 to 27 15.0 to 29.0
Mean (SD) 23 (5.2) 21 (4.0) 22 (4.7)
Median (IQR) 25 (19 to 29) 22 (17 to 25) 22 (18 to 26)
1 SD: standard deviation; 2 IQR: inter-quartile range; 3 TAU: Treatment as Usual; 4 CCBT: Computerised Cognitive Behavioural Therapy.
Cooper et al. Trials 2011, 12:259
http://www.trialsjournal.com/content/12/1/259
Page 5 of 14
Delivery of CCBT (home/external) and variation in
delivery and use
In the Sheffield region, Primary Care Trust (PCT) men-
tal health care teams administered the CCBT, facilitating
access and undertaking safety monitoring (PCTs were
publicly funded organisations responsible for commis-
sioning acute services for local populations). The CCBT
service provided to trial participants was the routine
Patients approached to take part
n=582
(Sheffield clinic, n=288; Liverpool mailout,
n=250; Sheffield neuropsychologist
mailout n=40; Sheffield MS nurses, n=4)
Responders
n=140 (24.1%)
(Sheffield clinic, n=63; Liverpool mailout,
n=64; Sheffield neuropsychologist mailout
n=9;  Sheffield MS nurses, n=4)
Non-responders
n=442 (75.9%)
Eligible
n=72 (12.4%)
Not eligible
n=68 (11.7%)
  Reasons:
  1)  BDI too high (n=20)
  2)  BDI too low (n=41)
  3)  Under care of psychiatrist (n=5)
  4)  Not resident in participating PCT
(n=2)
Consent and randomised
n=24 (4.1%)
Refused consent
n=48 (8.2%)
Allocated to TAU
n=12
Allocated to CCBT
n=12
Completed 8 weeks follow-up
n=12
Completed 8 weeks follow-up
n=9
Completed 21 weeks follow-up
n=8
Completed 21 weeks follow-up
n=10
Figure 1 CONSORT diagram.
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service provided to all patients referred to the PCT
mental health care teams. Only one out of the five parti-
cipating PCTs around the Sheffield centre formally pro-
vided any kind of community facility for accessing
CCBT; PCT staff warned that clients rarely used the
facility and it was closed during the course of the study.
Although four out of five participating PCTs were
happy to arrange alternative provision for those who did
not have Internet access at home, all our participants
requested home use of CCBT. In the Liverpool region, a
specialist neuropsychologist, based in the acute hospital
facilitated access to and provided technical advice on
CCBT, but did not provide additional therapeutic input.
No provision other than home-use was offered or
sought.
No PCT with whom we worked offered advice or sup-
port for defining problems on which to work or apply-
ing the CBT model to individual problems. The advice
given was essentially technical, focusing on using the
software. The PCTs delivering CCBT reported that they
assumed that patients who were non-adherent and non-
contactable beyond two weeks had discontinued treat-
ment and made no further effort to contact them. Some
but not all PCTs informed the patient’s GP in such a
situation. Preference for use at home amongst users in
the study was universal with no-one expressing a prefer-
ence for use of CCBT in an alternative location. Only
one participant in the TAU arm took up the offer of
access to CCBT at the end of the trial.
Withdrawal from treatment
Of the 12 patients in the CCBT arm, 9 (75%) completed
at least four CCBT sessions. This translated to a reason-
ably high compliance rate of CCBT although only six
(50%) of the patients in this arm completed all intended
eight CCBT sessions. Of these six patients, the median
Table 2 Questionnaire item response rates for available questionnaires
Questionnaire Follow up Time point Number of participants TAU % CCBT % Overall %
All TAU CCBT Min to max median Min to max median Min to max median
BDI 0 weeks 24 12 12 95-100 100 100-100 100 95-100 100
8 weeks 21 12 9 95-100 100 100-100 100 95-100 100
21 weeks 18 8 10 91-100 100 71-100 100 71-100 100
MSIS-29 0 weeks 23 11 12 96-100 100 100-100 100 96-100 100
8 weeks 20 12 8 96-100 100 100-100 100 96-100 100
21 weeks 19 10 9 96-100 100 96-100 100 96-100 100
PHQ-9 0 weeks 23 11 12 90-100 100 100-100 100 90-100 100
8 weeks 21 12 9 90-100 100 100-100 100 90-100 100
21 weeks 18 8 10 90-100 100 100-100 100 90-100 100
GAD-7 0 weeks 23 11 12 71-100 100 100-100 100 71-100 100
8 weeks 21 12 9 100-100 100 100-100 100 100-100 100
21 weeks 18 9 9 100-100 100 100-100 100 100-100 100
SF-36 0 weeks 23 11 12 91-100 100 97-100 100 91-100 100
8 weeks 21 12 9 66-100 100 100-100 100 66-100 100
21 weeks 19 9 10 94-100 100 100-100 100 94-100 100
Table 3 Summary measures of patient profiles for primary and secondary outcomes stratified by intervention group
Outcome Measure Follow -up TAU CCBT
BDI n Mean(SD) Median(IQR) Min-Max n Mean(SD) Median(IQR) Min-Max
Baseline 12 23.3(5.2) 24.5(19.0-28.5) 15.0-29.0 12 21.0(4.0) 22.0(17.0-25.0) 16.0-27.0
8 weeks 12 22.1(9.1) 20.0(18.0-25.0) 7.0-44.0 9 14.8(7.5) 16.0(8.0-21.0) 6.0-26.0
21 weeks 8 24.4(11.4) 21.5(18.0-33.0) 8.0-42.0 10 18.3(7.9) 17.0(11.0-24.0) 10.0-35.0
MSIS-29 subscale
Physical Baseline 11 60.7(20.9 68.0(38.0-78.0) 32.0-94.0 12 62.8(14.2) 65.0(50.5-71.5) 42.0-87.0
8 weeks 12 58.3(18.7) 60.5(42.5-74.0) 30.0-85.0 8 58.8(19.0) 65.5(40.0-71.0) 33.0-84.0
21 weeks 10 60.8(22.0) 57.5(44.0-81.0) 31.0-97.0 9 55.8(18.0) 58.0(43.0-65.0) 27.0-82.0
Psychological Baseline 11 27.3(8.2) 28.0(20.0-37.0) 15.0-38.0 12 28.8(6.2) 29.5(24.5-34.0) 18.0-37.0
8 weeks 12 26.8(8.9) 27.5(20.0-33.0) 14.0-43.0 8 23.4(10.3 25.5(13.0-29.5) 11.0-40.0
21 weeks 10 25.7(9.5) 24.0(16.0-33.0) 15.0-43.0 9 24.4(6.6) 22.0(21.0-31.0) 17.0-34.0
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time (IQR) to complete all eight CCBT sessions was 15
(13 to 20) weeks against an intended eight weeks time
frame. Only one person receiving CCBT formally
requested discontinuation of treatment (after Session 6
of 8) citing time and lack of enthusiasm as reasons. Of
the other non-completers, three also contributed quali-
tative data on their non-completion, one indicating lack
of time, one that she no longer felt the need for treat-
ment for her depression, and another citing computer
hardware issues.
Other concomitant service and medication use
Four participants received some kind of talking therapy
outside of the research protocol during the trial, one in
the CCBT arm and three in the TAU arm. Thirteen par-
ticipants received anti-depressants during the trial: seven
in the CCBT arm; six in the TAU arm.
Discussion
Recruitment to this study was slower than expected.
Dropouts and losses to follow-up were comparable with
studies evaluating CCBT in non-MS populations:
reported dropout rates for CCBT range from 0-75%
(mean percentage dropout rate 32%, SD 16.52), which is
comparable to dropout rates for other psychological
therapies [30]. Data collection by postal questionnaire
was challenging. Participants found problems with the
face validity of the depression inventories which include
somatic symptoms of depression which are also symp-
toms of MS (the BDI-II and the PHQ-9), despite the
fact that one has been psychometrically validated pre-
viously for use in people with MS by several research
teams [31,32]. The difficulties associated with assessing
mood in people with physical illness is recognised and
has been discussed previously [ 13,33]. However, the
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Figure 2 BDI-II patient profiles (n = 24).
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important point from this study is that participants
expressed concerns about completing the measures and
this may affect completion rates and validity in terms of
consistency of participants’ approach to responses
throughout the course of the study. If a study is to eval-
uate impact on a patient-important outcome measure
relevant to patients with MS then it should include the
MSIS-29, which provides a measure of the physical and
psychological impact of the condition from the patient’s
perspective [23]. This scale used on its own would
reduce the ability to compare outcomes with other stu-
dies so it should be used in addition to general popula-
tion scales such as the BDI, which has been used
extensively in the general population.
A recent systematic Cochrane review identified a
number of strategies proven to be effective in increas-
ing response to postal questionnaires [34]. Fortunately,
we had employed a few of these strategies including
using a short, personalised (screening) questionnaire
and including a second copy of the questionnaire at
follow up. We also highlighted the University’s involve-
ment in the study. However, any future study could
also employ other proven methods including using fol-
lowup contact, use of stamped returned envelopes (as
opposed to franked return envelopes), first class mail-
ing and assurance of confidentiality in the letter of
invitation.
Only a small percentage of people meeting the eligibil-
ity criteria for both MS and depression were successfully
consented into the study. The population approached
were not actively seeking treatment for mood-related
symptoms and this may have been a contributing factor
to the low consent rates. One other study has also iden-
tified that people with MS, while at higher risk of
depression, are rarely treatment-seeking, at least in a
primary care context [35].
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Figure 3 MSIS-29 Patient Profiles (n = 24).
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A limitation of this study is that it did not prospec-
tively define formal ‘stop/go’ criteria for a definitive
study, allowing researchers to assess the main study as
not feasible, feasible with protocol modifications, or fea-
sible without modifications (with or without close
ongoing monitoring of protocol feasibility and imple-
mentation). This was recommended as good practice for
pilot studies by Thabane and colleagues subsequent to
the finalisation of our protocol and our grant award
[16].
This pilot trial has demonstrated that recruitment of
the required sample size for a full trial from the relevant
population would be challenging as the numbers of par-
ticipants recruited per site were very low and a high
proportion of the prevalent cases had been approached
in the recruitment period. Consequently, extending the
recruitment period at particular centres would result in
diminishing returns in terms of participant recruitment.
Postal screening via the Walton Centre resulted in 10
participants in 5 months, face to face recruitment at
STH resulted in 14 participants in 9 months. From this
evidence a full trial of 180 participants would require at
least 13 sites, particularly considering that recruitment
may be slower in a full-scale trial, where a team is reli-
ant on other centres, than in a pilot study. This would
require the participation of all the large, research active
MS centres. Assuming 13 centres would be sufficient to
recruit the required sample, the time to obtain all the
necessary approvals and set up the sites would be con-
siderable and 12 months at minimum should be allowed
for this stage alone. In addition, time and resources
should be allocated to allow for recruitment of addi-
tional sites if necessary
As we have tested recruitment using both identifica-
tion of potential participants from an MS Register (Wal-
ton Centre) and through patient presentation at clinic
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(STH) either of these approaches could be utilised, so
the service configuration would not be a limitation.
However, the method of recruitment would also have to
be considered carefully as we focused on a population
who were screened for depression and not one which
was actively seeking help for depression; this may have
influenced the low uptake rate. In this regard, trialists
may be in a difficult position: on the one hand, people
with MS show unusually low levels of help-seeking for
their depression, making recruitment through systematic
mass screening more appealing [35]; on the other hand,
psychotherapeutic studies in which patients are
recruited through systematic screening rather than their
routine caregiver show significantly lower effect sizes
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Figure 5 MSIS-29 mean profile (complete cases n = 18).
Table 4 Variability in outcomes (all time points) by
intervention group
Outcome measure Intervention group Mean (SD)
TAU CCBT All
BDI 24.1 (9.0) 18.0 (6.7) 20.7 (8.3)
MSIS-29 subscale
Psychological 26.6 (8.6) 25.9 (7.7) 26.3 (8.2)
Physical 59.9 (19.9) 59.5 (16.5) 59.7 (18.2)
Mean and SD for BDI and MSIS-29 subscales based on data at all time-points
Table 5 Mean (SD) of change in primary and secondary
outcomes relative to their baseline measurements.
Outcome measure Follow-up TAU CCBT
BDI N Mean (SD) n Mean (SD)
8 weeks 12 -1.17 (8.1) 9 -5.33 (4.7)
21 weeks 8 0.25 (8.8) 10 -2.00 (5.1)
MSIS-29 subscale
Physical 8 weeks 11 -1.82 (7.8) 8 -7.00 (12.9)
21 weeks 10 -2.20 (11.0) 9 -7.89 (12.3)
Psychological 8 weeks 11 0.18 (5.1) 8 -5.88 (9.5)
21 weeks 10 -2.60 (5.6) 9 -4.33 (8.0)
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and the results of such a trial have poorer external
validity [36]. Considering all these factors for a future
full trial it may be better to extend the participant popu-
lation to include people with other neurological condi-
tions or even chronic conditions more widely. In
addition, the eligibility criteria could be extended to
include people with severe depression as in the ongoing
Randomised Evaluation of the Effectiveness and Accept-
ability of Computerised Therapy (REEACT) Trial
(ISRCTN 91947481). (Twenty respondents to our
screening questionnaire, who might otherwise have been
randomised, were excluded on the basis of experiencing
severe depression at two measurement points). However,
the sample size required to detect a difference may vary
as our estimations are not based on this population.
It would be essential to maximise participant follow-
up. A range of contact methods should be sought at the
outset including mobile phone numbers and e-mail
addresses. Sufficient resources would be required to
ensure persistent followup of non-responders.
A further consideration for any future trial relates to
the study design. The design of this study is described
as CCBT vs TAU as the participants in the CCBT arm
received CCBT in addition to any care, medication or
services they would have received if they had not been
part of the study. The TAU arm could be criticised as
not reflecting usual treatment for depression but being a
no-treatment arm (or TAU for MS) due to low levels of
help-seeking for depression by people with MS [35]. An
alternative approach would be to assess all participants
for depression and to agree clinical management prior
to randomisation. Those receiving TAU would therefore
be offered appropriate treatment for depression, those in
the treatment arm would receive CCBT in addition.
This would also ensure that screened patients who do
not meet the eligibility criteria on the basis of severity
of depression would receive the appropriate clinical care.
The time taken for participants to complete the study
intervention (13 to 20 weeks from randomisation) was
longer than expected or than recommended in the pro-
duct manual, due to the poor adherence of participants
with the weekly schedule. Adherence to treatment pro-
gramme timescales is difficult to guarantee where treat-
ment is delivered by local NHS services and not
delivered in ideal conditions by the trial team. Outcome
assessment time-points of future studies should be fixed
relative to the point of randomisation and not the pro-
jected end of the study intervention, as treatment pro-
grammes often over-run. This minimises discrepancies
between the timepoints at which the treatment and con-
trol participants are followed up. Fixed timepoint out-
come assessment should be supported by systems to
minimise mis-timed outcome measurements, for
instance automated follow-up reminders, pre-scheduled
follow-up appointments and requesting alternative and
preferred modes of contact (landline, mobile, text, e-
mail).
Participants in our previous related research reported
that they would value more support in defining their
problems and goals [15]. Since this research began, Spek
and colleagues have demonstrated that CCBT pro-
grammes are markedly more effective when delivered
with therapist support. However, in the PCTs with
whom we worked, therapist support was only available
Table 6 Sample size estimates for a definitive trial stratified by outcome measure, power and effect size
Outcome
measure
Power
(%)
Effect size Sample Size per
group
Total sample size (attrition
adjusted)
Approximate mean
difference
Standardised
BDI 90 5 0.6 35 70
3 0.3 90 180
2 0.2 195 390
80 5 0.6 25 50
3 0.3 65 130
2 0.2 145 290
MSIS-29 subscale
Psychological 90 3 0.3 95 190
2 0.2 220 410
80 3 0.3 70 140
2 0.2 155 310
Physical 90 6 0.3 115 230
4 0.2 260 520
80 6 0.3 85 170
4 0.2 195 390
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where issues remain unresolved after a complete course
of CCBT, although more recently, through the ‘Improv-
ing Access to Psychological Therapies’ service, the sup-
port of a psychological wellbeing practitioner within
primary care should be available within the stepped care
model recommended by NICE [8]. Whether such sup-
port is in fact available is likely to vary between sites [7].
Any future research protocol would have to balance the
desire to provide and evaluate an optimised intervention
(CCBT with concurrent therapist support) against the
likelihood of therapist-supported CCBT becoming the
norm in the UK healthcare setting. In either case, study
teams should report any standardisation or variation in
the implementation of the intervention (for instance in
the level of therapist support) between study sites in
line with the CONSORT modification proposed by
Zwarenstein and colleagues [17]. We would not recom-
mend evaluating the delivery of CCBT in community
facilities as our experience here has shown that many
NHS partners are not delivering it in this way and parti-
cipants overwhelmingly chose to access CCBT at home.
More successful models of delivering CCBT and
implementing future interventional research might be
through either (a) the secondary care multi-disciplinary
neurology teams (see for example work by Moss-Morris
and colleagues [37]) or (b) Psychological Wellbeing
Practitioners based in primary care trained by clinical
neuropsychologists in the issues they need to know to
support CCBT use in patients with MS. The commercial
company which produces Beating the Blues® (Ultrasis)
has indicated that it intends to address the issues of
appropriateness and acceptability of Beating the Blues®
to people with MS identified in our previous work [14]
in future product developments. The choice of CCBT to
be used in any future full trial should take into consid-
eration whether these issues have been addressed and
the range of alternative CCBT packages which may be
available in the future.
Conclusions
The results of this pilot study demonstrate that, if the
intended full trial of the clinical and cost-effectiveness
of CCBT for depression in people with MS were to pro-
ceed, a number of amendments to the pilot trial proto-
col would be required. A definitive RCT, with a
recruitment window of one year, would require the par-
ticipation of around 13 UK MS centres. This number
could be reduced by expanding the eligibility criteria to
include either other neurological conditions or people
with more severe depression. The design of the defini-
tive study will need to consider whether to optimise the
delivery of CCBT through the provision of therapist
support depending on the likelihood of this being deli-
verable in routine practice. Participants should access
CCBT at home in line with patient-preference and
because NHS partners are not typically delivering it in
community facilities. Finally, the MSIS-29 should be
used as a patient-important outcome measurement.
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